Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Negative 95.8%

Neg 95.8% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and maintains $7 price target.